BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22804747)

  • 1. KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas.
    Alexander RE; Lopez-Beltran A; Montironi R; MacLennan GT; Post KM; Bilbo SA; Jones TD; Huang W; Rao Q; Sen JD; Meehan K; Cornwell A; Miravalle L; Cheng L
    Histopathology; 2012 Dec; 61(6):1036-42. PubMed ID: 22804747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].
    Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [KRAS gene mutation in colorectal cancer].
    Roa I; Sánchez T; Majlis A; Schalper K
    Rev Med Chil; 2013 Sep; 141(9):1166-72. PubMed ID: 24522420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.
    Karkouche R; Bachet JB; Sandrini J; Mitry E; Penna C; Côté JF; Blons H; Penault-Llorca F; Rougier P; Saint André JP; Emile JF
    Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1430-7. PubMed ID: 23114745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
    Riely GJ; Johnson ML; Medina C; Rizvi NA; Miller VA; Kris MG; Pietanza MC; Azzoli CG; Krug LM; Pao W; Ginsberg MS
    J Thorac Oncol; 2011 Aug; 6(8):1435-7. PubMed ID: 21847063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
    Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
    Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
    Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
    J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder and gastric metastases from lung adenocarcinoma harboring codon 13 KRAS mutation: a case report with unusual clinical outcome.
    Galetta D; Catino A; Misino A; De Ceglie A; Logroscino A; Simone G; Natalicchio MI
    Tumori; 2015 Sep; 101(5):e138-40. PubMed ID: 26045124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.
    Munfus-McCray D; Cui M; Zhang Z; Gabrielson E; Askin F; Li QK
    Hum Pathol; 2013 Jul; 44(7):1286-92. PubMed ID: 23337026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
    Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of polypoid colorectal adenocarcinoma with pre-existing adenomatous polyps and KRAS mutation.
    Chen H; Lefferts JA; Schwab MC; Suriawinata AA; Tsongalis GJ
    Cancer Genet; 2011 May; 204(5):245-51. PubMed ID: 21665177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR and KRAS mutations in metastatic lung adenocarcinomas.
    Munfus-McCray D; Harada S; Adams C; Askin F; Clark D; Gabrielson E; Li QK
    Hum Pathol; 2011 Oct; 42(10):1447-53. PubMed ID: 21497370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.